معرفی
Paul B. Lawrence serves as a Lecturer at the University of Central Florida with academic training spanning Brigham Young University and the University of Washington. His research bridges biochemical engineering and oncology through advanced protein modification techniques.
His core research focuses on:
- Site-specific protein PEGylation and conformational stability engineering
- Mechanistic analysis of p53 tumor suppressor post-translational modifications (SUMOylation, phosphorylation, acetylation)
- Protein semisynthesis methodologies including expressed protein ligation and protein trans-splicing
- Cancer therapeutics development targeting p53 dysregulation pathways
Dr. Lawrence pioneered synthesis of SUMOylated p53 at lysine 386 and wild-type p53 variants, validating functionality through DNA-binding assays and in vitro transcription systems developed in collaboration with Rockefeller University's Roeder Laboratory. His work establishes critical structure-function relationships between PTM patterns and p53 oncogenic behavior.
No scientific awards are documented in available materials.
Student advising details and grant funding history remain unspecified in provided documentation, though his postdoctoral work in Dr. Champak Chatterjee's laboratory demonstrates extensive collaborative research experience.
His laboratory expertise encompasses E. coli protein expression systems, milligram-scale protein purification, structural refolding protocols, and cross-institutional validation of protein function through specialized biochemical assays.
